A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC)

Protocol No

PULM-ACCELERON-ZENITH

Phase

III

Summary

This project is being done to determine the efficacy and effect of sotatercept on patients with PAH through a series of clinical test and questionnaires.

Description

Sotatercept in Participants With Pulmonary Arterial Hypertension WHO FC III or FC IV at High Risk of Mortality

Participating Institutions

Froedtert Hospital

Status

OPEN TO ACCRUAL

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) World Health Organization (WHO) Functional Class (FC) III or FC IV at High Risk Mortality